<DOC>
	<DOCNO>NCT00366093</DOCNO>
	<brief_summary>To demonstrate improved subjective sleep woman insomnia secondary perimenopause menopause follow treatment 3 mg eszopiclone .</brief_summary>
	<brief_title>Study Eszopiclone Compared Placebo Treatment Insomnia Secondary Perimenopause/Menopause</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , placebo-controlled , parallel-group study eszopiclone 3 mg woman insomnia secondary perimenopause menopause . Eligible subject randomize either eszopiclone 3 mg placebo nightly four week . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Inclusion Criteria Subject must understand purpose study willing adhere study schedule procedure describe protocol . Subject must age 40 60 year , inclusive , day sign consent . Subject must perimenopausal menopausal sign symptom . Subject must report SL &gt; 45 minute &lt; 6 hour TST least three time week previous month symptom insomnia must post date onset perimenopausal menopausal symptom . Subject 's physical exam must show clinically significant abnormal finding ( insomnia menopause symptom ) screen . Exclusion Criteria Subject history circadian rhythm disorder , travel across &gt; 3 time zone regular basis . Female subject pregnant , lactate within 6months post partum . Subject history drug alcohol abuse dependence past 2 year positive urine drug test screening . Subject unstable medical abnormality , unstable chronic disease ; history significant cardiac , renal , hepatic disease , seizure disorder , current past acute suicidal tendency . Subject participate investigational drug study within 30 day prior screen plan participate another investigational drug study participation study . Subject take hormone replacement therapy hormonal contraceptive , stable dose minimum 60 day prior study start . Subject know seropositive HIV . Subject disorder history condition ( e.g. , malabsorption , gastrointestinal surgery ) may interfere drug absorption distribution , metabolism , excretion . Subject history malignancy within 5 year , current malignancy , except nonmelanoma skin cancer . Subject diagnosis psychiatric disorder identify psychiatric screening questionnaire . Subject primary diagnosis ( personality disorder mental retardation ) would impact investigator 's ability evaluate safety efficacy study medication . Subject difficulty sleep initiation maintenance associate known primary sleep disorder [ e.g . sleep apnea , restless leg syndrome ( RLS ) , periodic leg movement syndrome ( PLMS ) ] , condition may affect sleep ( e.g. , chronic pain , urinary incontinence , etc. ) . Subject used drug know suspected affect hepatic renal clearance capacity within period 30 day prior screen . Subject report consumption two alcoholic beverage daily , 14 alcoholic beverage weekly , five alcoholic beverage give day . Subject rotate third/night shift worker . Subject staff member relative staff member . Subject experience symptoms premature menopause surgical menopause . Subject discontinue hormone replacement therapy hormonal contraceptive , treatment minimum 60 day prior study start . Subject hormone replacement therapy hormonal contraceptive great one year .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Perimenopause</keyword>
</DOC>